目前的景观,含有抗结肠直肠癌潜力的酸混合体
Yanjing Cheng1,2, Yafei Zhuang1, Ni Zhu2
1School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei, China.
胺酸杂交物显示为治疗结直肠癌的基因脱乙酶 (HDAC) 抑制剂具有前途. 这些化合物向多种途径,有可能提高癌症治疗的疗效和减少副作用.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 结肠直肠癌是全球主要的恶性瘤,对健康构成重大风险.
- 它是全球第三常见的癌症,约占新病例的10%.
- 有效的治疗策略对于对抗这种疾病至关重要.
研究的目的:
- 审查胺酸杂交物作为潜在的抗结肠直肠癌药物的最新进展.
- 探索它们的作用机制,专注于素脱乙酶 (HDAC) 抑制.
- 确定结直肠癌治疗的新型治疗候选者.
主要方法:
- 在2020年至今期间开发的胺酸混合体的文献综述.
- 分析它们作为基因素脱乙酶 (HDAC) 抑制剂的潜力.
- 评估它们的多目标治疗能力.
主要成果:
- 酸混合体通过多个途径显示出潜在的抗结肠直肠癌效应.
- 这些化合物可以抑制关键的分子和细胞过程,驱动瘤生长和转移.
- 同时针对多个癌症部位可能会提高疗效并克服耐药性.
结论:
- 胺酸杂交物代表着结直肠癌治疗中一个有前途的化合物类.
- 它们作为HDAC抑制剂和向多个途径的能力提供了治疗优势.
- 对这些新型候选人的进一步研究可能会导致改善结直肠癌治疗方法.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Drugs that Stabilize Microtubules
Drugs for Treatment of Ulcerative Colitis in IBD
